Compare Inovio Pharmaceuticals Inc (INO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 240× Inovio Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Verisign, Inc. for 123 Days on average.
| INO | VRSN | |
|---|---|---|
Market Cap | $112.19M | $26.92B |
Volume | 3,201,278 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $2.65 | $310.00 |
52-Week Low | $0.66 | $211.49 |
Typical Hold Time | 43 Days | 123 Days |
Enterprise Value | $83.51M | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
VeriSign (VRSN) trades at $303.74, up 3.24% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 49.77% net income margin and consistent revenue growth, reaching $1.66B in 2025. Recent news includes an upcoming Q3 2026 earnings call and insider selling by the CEO, while institutional buying from firms like BlackRock signals confidence. A class-action antitrust lawsuit filed in September 2026 poses a regulatory risk.
The investment outlook is positive, driven by analyst consensus favoring a buy rating with a $348 price target, implying 15% upside. Key opportunities include AI-driven domain growth and a pending .com price increase. Risks involve the antitrust litigation, competitive pressures, and reliance on domain registry revenues. Earnings momentum is mixed, with Q2 2026 missing estimates but Q1 beating expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
